

Agile Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 07-Mar-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 9

 Pre-registration..... 10

 Phase 2 Clinical..... 16

 Discovery..... 23

[Return to Table of Contents](#)

Agile Therapeutics Inc

COMPANY OVERVIEW

| | |
|--|--|
| Company Name | Agile Therapeutics Inc |
| Parent Company Name | Agile Therapeutics Inc |
| Website | http://www.agiletherapeutics.com/ |
| Country | US |
| Number of Drugs in Active Development | 3 |
| Number of Inactive Drugs | 0 |
| Number of Patents as Owner | 8 |
| Number of Patents as Third Party | 2 |
| Number of Deals | 2 |
| Key Indications | Female contraception,Depression,Parkinsons disease,Alzheimers disease,Central nervous system disease,Migraine,Nausea,Pain |
| Key Target-based Actions | Progesterone receptor agonist,Estrogen receptor agonist,5-HT 3 receptor antagonist,MAO B inhibitor |
| Key Technologies | Patch formulation,Transdermal formulation,Small molecule therapeutic,Absorption enhancer transdermal,Drug combination,Formulation preservation,Absorption enhancer,Controlled release formulation,Matrix |

COMPANY PROFILE

SUMMARY

Agile Therapeutics, founded in 1997, is a late-stage, privately-held pharmaceutical company focusing on women's health products.

FINANCIAL

In February 2015, a first tranche of \$16.5 million was funded upon execution of the loan agreement and \$15.5 million would be used to repay Agile's existing term loan facility. Under the terms of the loan agreement, Agile was not obligated to draw an additional tranche of up to \$8.5 million prior to July 1, 2016, subject to the achievement of certain clinical milestones, which may be extended to December 31, 2016. At that time, Agile issued Hercules a warrant to purchase 180,274 shares of Agile common stock at an exercise price of \$5.89 each.

In January 2015, the company entered into a definitive stock purchase agreement with a group of institutional accredited investors for the private placement of 3.4 million of common stock shares at \$5.85 per share and the gross proceeds were expected to be \$20 million. At that time, the private placement was expected to close on or about January 23, 2015.

In June 2014, the company's stock was added to the Russell Microcap Index.

In March 2014, Agile filed form S-1 with the US SEC for a proposed IPO of common stock. In May 2014, the company priced the offering of 9,166,667 shares at \$6 per share. The underwriters were granted a 30-day option to buy up to an aggregate of 1,375,000 additional shares of common stock, to cover any over-allotments. The offering was expected to close on May 29, 2014. At that time, the shares were expected to initiate trading on the NASDAQ Global Market, on May 23, 2014, under the symbol "AGRX".

In January 2013, the company closed a term loan facility for up to \$15 million with Oxford Finance.

In July 2012, the company raised \$40 million from a series C financing.

In June 2010, Agile raised \$45 million from a series B preferred stock financing.

In December 2007, Agile raised \$5.6 million from a series E financing round.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|---------------------------|--------|----------|-------|
| Prophylaxis | 3 | 0 | 3 |
| Gynecology and obstetrics | 3 | 0 | 3 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Pre-registration | 1 |
| Phase 2 Clinical | 1 |
| Discovery | 1 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|-----------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drug - Manufacturing/Supply | 0 | 0 | 1 | 0 | 1 |
| Drug - Development Services | 0 | 0 | 1 | 0 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|---------------------------|---------|-----|
| Gynecology and obstetrics | 0 | 4 |
| Prophylaxis | 0 | 4 |

[Return to Table of Contents](#)



Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 3 | 1 | 4 |
| Phase 2 | 0 | 3 |
| Phase 1 | 0 | 4 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|---------------------------|----------|----------------|-------|
| Gastrointestinal disease | 0 | 1 | 1 |
| Degeneration | 0 | 1 | 1 |
| Psychiatric disorder | 0 | 2 | 2 |
| Neurological disease | 0 | 2 | 2 |
| Prophylaxis | 11 | 0 | 11 |
| Gynecology and obstetrics | 11 | 0 | 11 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile

ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile SNAPSHOT

| | |
|----------------------|---|
| Drug Name | ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile |
| Key Synonyms | Twirla |
| Originator Company | Agile Therapeutics Inc |
| Active Companies | Agile Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Pre-registration |
| Active Indications | Female contraception |
| Target-based Actions | Estrogen receptor agonist;Progesterone receptor agonist |
| Other Actions | Female contraceptive |
| Technologies | Patch formulation;Absorption enhancer transdermal;Small molecule therapeutic;Drug combination;Transdermal formulation |
| Last Change Date | 25-Feb-2015 |

ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile DEVELOPMENT PROFILE

SUMMARY

Agile Therapeutics is developing AG-200-15 (Twirla), a low-dose weekly patch containing ethinylestradiol (EE) and levonorgestrel (LNG), based on company's Skinfusion technology, for the potential use as a female contraceptive. In April 2012, an NDA was submitted to the FDA; in July 2012, the NDA was accepted by the FDA. In September 2014, approval was expected later in 2016.



ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|------------------------|----------------------|---------|--------------------|-------------|
| Agile Therapeutics Inc | Female contraception | US | Pre-registration | 30-Apr-2012 |


ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile CHEMICAL STRUCTURES

[Return to Table of Contents](#)

| CAS Registry Number: | Confidence Level: |
|--|-------------------|
| | 1 |
|   | |
| Name | Type |
| Miranova | Trade Name |
| Levlite | Trade Name |
| DR-103 | Research Code |
| AG-200-15 | Research Code |
| ethinylestradiol + levonorgestrel | |

| CAS Registry Number: | Confidence Level: |
|---|-------------------|
| 57-63-6 | 1 |
|  | |
| Name | Type |
| ethinylestradiol | BANN; INN |
| ethynylestradiol | USAN |
| ethinyl estradiol | USAN |

[Return to Table of Contents](#)

| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| 797-63-7 | 1 |
|  | |
| Name | Type |
| levonorgestrel | BANN; INN |
| NorLevo | Trade Name |
| Skyla | Trade Name |

ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile DRUG NAMES

| | |
|--|---------------|
| Names | Type |
| AG-200-15 | Research Code |
| Twirla | Trade Name |
| ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile | |
| ethinylestradiol + levonorgestrel | |

ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile CLINICAL TRIALS

Trials by Phase and Condition Studied

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|----------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Female contraception | | | | | | | | | | | |
| 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 3 |

[Return to Table of Contents](#)

Total Trials by Phase and Status

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|---------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Total by Phase and Status | | | | | | | | | | | |
| 0 | 0 | 1 | 4 | 0 | 3 | 0 | 3 | 0 | 0 | 1 | 10 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

ethinylestradiol + levonorgestrel (female contraception, patch, Skinfusion), Agile DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 1


Agile Therapeutics Inc
Corium International Inc

[Return to Table of Contents](#)

Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|--------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Agile Therapeutics Inc | 0 | 0 | 1 | 0 | 1 |
| Corium International Inc | 1 | 0 | 0 | 0 | 1 |

Deals by Type Chart




Deals by Type Table

| Deal Type | Active | Inactive | Total |
|-----------------------------|--------|----------|-------|
| Drug - Manufacturing/Supply | 1 | 0 | 1 |

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

| Company Name | As Owner | As Third Party | Total |
|------------------------|----------|----------------|-------|
| Agile Therapeutics Inc | 10 | 0 | 10 |
| Rutgers University | 0 | 1 | 1 |

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

| Drug Relationship | Total |
|-------------------|-------|
| Formulation | 7 |
| Tentative | 1 |
| Product | 1 |
| Delivery device | 1 |

[Return to Table of Contents](#)

levonorgestrel (Skinfusion patch, female contraception), Agile

levonorgestrel (Skinfusion patch, female contraception), Agile SNAPSHOT

| | |
|----------------------|--|
| Drug Name | levonorgestrel (Skinfusion patch, female contraception), Agile |
| Key Synonyms | levonorgestrel |
| Originator Company | Agile Therapeutics Inc |
| Active Companies | Agile Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Female contraception |
| Target-based Actions | Progesterone receptor agonist |
| Other Actions | Female contraceptive |
| Technologies | Patch formulation;Small molecule therapeutic;Transdermal formulation |
| Last Change Date | 09-Apr-2014 |

levonorgestrel (Skinfusion patch, female contraception), Agile DEVELOPMENT PROFILE

SUMMARY

Agile Therapeutics is developing AG-890 (AG-900, AG-1000), a low-dose weekly patch containing levonorgestrel, based on company's Skinfusion technology, for the potential use as a contraceptive in breast-feeding mothers and women with contraindications to estrogen,. By January 2011, a phase I/II trial had been initiated of two different doses (AG-1000-6.5 and AG-1000-12.5). In July 2012, the drug was listed as being in phase II development ; in March 2014, this was still the case and at that time, an NDA filing was expected in 2015 .

levonorgestrel (Skinfusion patch, female contraception), Agile DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|------------------------|----------------------|---------|--------------------|-------------|
| Agile Therapeutics Inc | Female contraception | US | Phase 2 Clinical | 09-Jan-2011 |

levonorgestrel (Skinfusion patch, female contraception), Agile CHEMICAL STRUCTURES

[Return to Table of Contents](#)



| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| 797-63-7 | 1 |
|  | |
| Name | Type |
| levonorgestrel | BANN; INN |
| NorLevo | Trade Name |
| Skyla | Trade Name |

levonorgestrel (Skinfusion patch, female contraception), Agile DRUG NAMES

| Names | Type |
|---|---------------|
| progestin-only patch (transdermal contraceptive delivery system), Agile | |
| AG-890-6.5 | Research Code |
| AG-890 | Research Code |
| AG-1000-12.5 | Research Code |
| AG-1000 | Research Code |
| AG-890-12.5 | Research Code |
| levonorgestrel (Skinfusion patch, female contraception), Agile | |
| levonorgestrel | BANN, INN |
| AG-1000-6.5 | Research Code |
| AG-900 | Research Code |

levonorgestrel (Skinfusion patch, female contraception), Agile CLINICAL TRIALS

Trials by Phase and Condition Studied

[Return to Table of Contents](#)

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|----------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Female contraception | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |

Total Trials by Phase and Status

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|---------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Total by Phase and Status | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|--------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Agile Therapeutics Inc | 0 | 0 | 2 | 0 | 2 |
| US Government | 1 | 0 | 0 | 0 | 1 |
| Corium International Inc | 1 | 0 | 0 | 0 | 1 |

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

| Deal Type | Active | Inactive | Total |
|-----------------------------|--------|----------|-------|
| Drug - Manufacturing/Supply | 1 | 0 | 1 |
| Drug - Development Services | 1 | 0 | 1 |

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

| Company Name | As Owner | As Third Party | Total |
|------------------------|----------|----------------|-------|
| Agile Therapeutics Inc | 2 | 0 | 2 |
| Individual | 1 | 0 | 1 |

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

| Drug Relationship | Total |
|-------------------|-------|
| Formulation | 1 |
| Delivery device | 1 |

undisclosed patch programs (female contraception), Agile Therapeutics

undisclosed patch programs (female contraception), Agile Therapeutics SNAPSHOT

| | |
|----------------------|--|
| Drug Name | undisclosed patch programs (female contraception), Agile Therapeutics |
| Key Synonyms | |
| Originator Company | Agile Therapeutics Inc |
| Active Companies | Agile Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Female contraception |
| Target-based Actions | |
| Other Actions | Contraceptive;Unspecified drug target |
| Technologies | Patch formulation;Absorption enhancer transdermal;Small molecule therapeutic;Transdermal formulation |
| Last Change Date | 17-Mar-2014 |

undisclosed patch programs (female contraception), Agile Therapeutics DEVELOPMENT PROFILE

SUMMARY

Agile is investigating a program of contraceptive patches, based on company's Skinfusion technology, for the potential use as a female contraceptive. In July 2012, the program was listed as being in preclinical development; at that time the leads from the program were ready to move into clinical development ; in March 2014, this was still the case.

undisclosed patch programs (female contraception), Agile Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|------------------------|----------------------|---------|--------------------|-------------|
| Agile Therapeutics Inc | Female contraception | US | Discovery | 27-Jul-2012 |

undisclosed patch programs (female contraception), Agile Therapeutics DRUG NAMES

| Names | Type |
|---|------|
| undisclosed patch programs (female contraception), Agile Therapeutics | |

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

